Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-α: A potential role in systemic lupus erythematosus

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 383-394

  Asokan, Rengasamy ^a   Hua, Jing ^b   Young, Kendra A ^a   Gould, Hannah J ^c   Hannan, Jonathan P ^a   Kraus, Damian M ^a   Szakonyi, Gerda ^a   Grundy, Gabrielle J ^e   Chen, Xiaojiang S ^d   Crow, Mary K ^b   Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BIOTIN; CD23 ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENTARY DNA; GLYCOPROTEIN GP 350; HOLOENZYME; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BIOTINYLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING;

EID: 33745298439     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.383     Document Type: Article

References (71)

1. Iida, K., L. Nadler, and V. Nussenzweig. 1983. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J. Exp. Med. 158: 1021-1033.
2. Fingeroth, J. D., J. J. Weis, T. F. Tedder, J. L. Strominger, P. A. Biro, and D. T. Fearon. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81: 4510-4514.
3. Aubry, J. P., S. Pochon, P. Graber, K. U. Jansen, and J. Y. Bonnefoy. 1992. CD21 is a ligand for CD23 and regulates IgE production. Nature 358: 505-507.
4. Aubry, J. P., S. Pochon, J. F. Gauchat, A. Nueda-Marin, V. M. Holers, P. Graber, C. Siegfried, and J. Y. Bonnefoy. 1994. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 152: 5806-5813.
5. Holers, V. M. 2001. Complement. In Principles and Practices of Clinical Immunology. R. Rich, ed. Mosby, St. Louis, pp. 21.1-21.8.
6. Szakonyi, G., J. M. Guthridge, D. Li, K. Young, V. M. Holers, and X. S. Chen. 2001. Structure of complement receptor 2 in complex with its C3d ligand. Science 292: 1725-1728.
7. Prota, A. E., D. R. Sage, T. Stehle, and J. D. Fingeroth. 2002. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 99: 10641-10646.
8. Morikis, D., and J. D. Lambris. 2004. The electrostatic nature of the C3d-complement receptor 2 association. J. Immunol. 172: 7537-7547.
9. Gilbert, H. E., J. T. Eaton, J. P. Hannan, V. M. Holers, and S. J. Perkins. 2005. Solution structure of the complex between CR2 SCR1-2 and C3d of human complement: an X-ray scattering and sedimentation modeling study. J. Mol. Biol. 346: 859-873.
10. Hannan, J. P., K. A. Young, J. M. Guthridge, R. Asokan, G. Szakonyi, X. S. Chen, and V. M. Holers. 2005. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interactions reveals a putative charged SCR1 binding site for C3d. J. Mol. Biol. 346: 845-858.
11. Carter, R. H., M. O. Spycher, Y. C. Ng, R. Hoffman, and D. T. Fearon. 1988. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J. Immunol. 141: 457-463.
12. Kozono, Y., R. Abe, H. Kozono, R. G. Kelly, T. Azuma, and V. M. Holers. 1998. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 160: 1565-1572.
13. Boackle, S. A., V. M. Holers, X. Chen, G. Szakonyi, D. R. Karp, E. K. Wakeland, and L. Morel. 2001. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15: 775-785.
14. Poe, J. C., M. Hagesawa, and T. F. Tedder. 2001. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int. Rev. Immunol. 20: 739-762.
15. Lyubchenko, T., J. dal Porto, J. C. Cambier, and V. M. Holers. 2005. Co-ligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J. Immunol. 174: 3264-3272.
16. Fearon, D. T., and R. H. Carter. 1995. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13: 127-149.
17. Tedder, T. F., L. J. Zhou, and P. Engel. 1994. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 15: 437-442.
18. Bradbury, L. E., G. S. Kansas, S. Levy, R. L. Evans, and T. F. Tedder. 1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149: 2841-2850.
19. Sugano, N., W. Chen, M. L. Roberts, and N. R. Cooper. 1997. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kB induction. J. Exp. Med. 186: 731-737.
20. D'Addario, M., T. A. Libermann, J. Xu, A. Ahmad, and J. Menezes. 2001. Epstein-Barr virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-κB and different signaling pathways. J. Mol. Biol. 308: 501-514.
21. Boackle, S. A., M. A. Morris, V. M. Holers, and D. R. Karp. 1998. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J. Immunol. 161: 6537-6543.
22. Cherukuru, A., P. C. Cheng, and S. K. Pierce. 2001. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167: 163-172.
23. Melamed, I., L. Stein, and C. M. Roifman. 1994. Epstein-Barr virus induces actin polymerization in human B cells. J. Immunol. 158: 1998-2003.
24. Bonnefoy, J. Y., S. Henchoz, D. Hardie, M. J. Holder, and J. Gordon. 1993. A subset of anti-CD21 antibodies promote the rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23: 969-972.
25. + T cell clones. Eur. J. Immunol. 24: 2982-2986.
26. Bjork, P., C. Elenstrom-Magnusson, A. Rosen, E. Severinson, and S. Paulie. 1993. CD23 and CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes. Eur. J. Immunol. 23: 1771-1775.
27. Molina, H., T. Kinoshita, K. Inoue, J.-C. Carel, and V. M. Holers. 1990. A molecular and immunochemical characterization of mouse CR2: evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 145: 2974-2983.
28. Ahearn, J. M., M. B. Fischer, D. A. Croix, S. Georg, M. Ma, J. Xia, X. Zhou, R. G. Howard, T. L. Rothstein, and M. C. Carroll. 1996. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4: 251-262.
29. Molina, H., V. M. Holers, B. Li, Y.-F. Fang, S. Mariathasan, F. Goellner, J. Strauss-Schoenberger, R. W. Karr, and D. D. Chaplin. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93: 3357-3361.
30. Haas, K. M., M. Hasegawa, D. A. Steeber, J. C. Poe, M. D. Zabel, C. B. Bock, D. R. Karp, D. E. Briles, J. H. Weis, and T. F. Tedder. 2002. Complement receptors CD21/35 link innate and protective immunity during Streptococcus phenumoniae infection by regulating IgG3 antibody responses. Immunity 17: 713-723.
31. Fischer, M. B., S. Goerg, L. Shen, A. P. Prodeus, C. C. Goodnow, G. Kelsoe, and M. C. Carroll. 1998. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280: 582-585.
32. -/- mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 165: 3119-3127.
33. Barrington, R. A., O. Pozdnyakova, M. R. Zafari, C. D. Benjamin, and M. C. Carroll. 2002. B lymphocyte memory: role of stromal cell complement and FcyRIIB receptors. J. Exp. Med. 196: 1189-1199.
34. Fleming, S. D., T. Shea-Donohue, J. M. Guthridge, L. Kulik, T. J. Waldschmidt, M. G. Gipson, G. C. Tsokos, and V. M. Holers. 2002. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 169: 2126-2133.
35. Reid, R. R., S. Woodstock, A. Shimabukuro-Vornhagen, W. G. Austen, Jr., L. Kobzik, M. Zhang, H. B. Hechtman, F. D. Moore, Jr., and M. C. Carroll. 2002. Functional activity of natural antibody is altered in Cr2-deficient mice. J. Immunol. 169: 5433-5440.
36. Prodeus, A., S. Goerg, L.-M. Shen, O. O. Pozdnyakova, L. Chu, E. M. Alicot, C. C. Goodnow, and M. C. Carroll. 1998. A critical role for complement in maintenance of self-tolerance. Immunity 9: 721-731.
37. Wu, X., N. Jiang, C. Deppong, J. Singh, G. J. Dolecki, D. Mao, L. Morel, and H. D. Molina. 2002. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 169: 1587-1592.
38. Paul, E., O. O. Pozdnyakova, E. Mitchell, and M. C. Carroll. 2002. Anti-DNA autoreactivity in C4-deficient mice. Eur. J. Immunol. 32: 2672-2679.
39. Wilson, J. G., W. D. Ratnoff, P. H. Schur, and D. T. Fearon. 1986. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 29: 739-747.
40. Takahashi, K., Y. Kozono, T. J. Waldschmidt, D. Berthiaume, R. J. Quigg, A. Baron, and V. M. Holers. 1997. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J. Immunol. 159: 1557-1569.
41. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615.
42. Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
43. Delcayre, A. X., F. Salas, S. Mathur, K. Kovats, M. Lotz, and W. Lernhardt. 1991. Epstein-Barr virus/complement C3d receptor is an interferon-α receptor. EMBO J. 10: 919-926.
44. Delcayre, A. X., M. Lotz, and W. Lernhardt. 1993. Inhibitions of Epstein-Barr virus-mediated capping of CD21/CR2 by α interferon (IFN-α): immediate antiviral activity of IFN-α during the early phase of infection. J. Virol. 67: 2918-2921.
45. Molina, H., S. J. Perkins, J. Guthridge, J. Gorka, T. Kinoshita, and V. M. Holers. 1995. Characterization of a complement receptor 2 (CD2, CD21) ligand binding site for C3: an initial model of ligand interaction with two linked SCR modules. J. Immunol. 154: 5426-1535.
46. Sarrias, M. R., S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris. 2001. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J. Immunol. 167: 1490-1499.
47. Weis, J. J., S. A Richards., J. A. Smith, and D. T. Fearon. 1986. Purification of the B lymphocyte receptor for the C3d fragment of complement and the Epstein-Barr virus by monoclonal antibody affinity chromatography, and assessment of its functional capacities. J. Immunol. Methods 92: 79-87.
48. Guthridge, J. M., J. K. Rakstang, K. Young, J. Hinshelwood, M. Aslam, A. Robertson, M. G. Gipson, M.-R. Sarrias, W. T. Moore, M. Meagher, et al. 2001. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 40: 5932-5941.
49. Henson, S. E., D. Smith, S. A. Boackle, V. M. Holers, and D. R. Karp. 2001. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Methods 258: 97-109.
50. Hedrick, J. A., Z. Lao, S. G. Lipps, Y. Wang, S. C. Todd, J. D. Lambris, and C. D. Tsoukas. 1994. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells. J. Immunol. 153: 4418-4426.
51. Bohmann, D., and R. Tijan. 1989. Biochemical analysis of transcriptional activation by Jun: differential activity of c- and v-Jun. Cell 59: 709-117.
52. Taylor, M. A. 1992. Active papain renatured and processed from insoluble recombinant propapain expressed in Escherichia coli. Protein Eng. 5: 455-459.
53. Guthridge, J. M., K. Young, M. G. Gipson, M.-R. Sarrias, G. Szakonyi, X. S. Chen, A. Malaspina, E. Donoghue, J. A. James, J. D. Lambris, et al. 2001. Epitope mapping using the x-ray crystallographic structure of complement receptor type 2 (CR2/CD21): identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 167: 5758-5866.
54. Kirou, K. A., C. Lee, S. George, K. Louca, I. G. Papaginnis, M. G. Peterson, N. Ly, R. N. Woodward, K. E. Fry, A.Y. Lau, et al. 2004. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50: 3958-3967.
55. Martin, D. R., A. Uryev, K. R. Kalli, D. T. Fearon, and J. M. Aheam. 1991. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor 2. J. Exp. Med. 174: 1299-1311.
56. Bancherau, J., V. Pascual, and A. K. Palucka. 2004. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20: 539-550.
57. Chada, S., R. Ramesh, and A. M. Mhashilkar. 2003. Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther. 5: 463-474.
58. Ioannou, Y., and D. A. Eisenberg. 2000. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43: 1431-1442.
59. Hooks, J. J., H. M. Moutsopoulos, S. A. Geis, N. I. Stahl, J. L. Decker, and A. L. Notkins. 1979. Immune interferon in the circulation of patients with autoimmune diseases. N. Engl. J. Med. 301: 5-8.
60. Jego, G., A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Bancherau. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234.
61. Pogue, S. L., B. T. Preston, J. Stalder, C. R. Bebbington, Cardare, and P. M. Cardarelli. 2004. The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J. Interferon Cytokine Res. 24: 131-139.
62. Braun, D., I. Caramalho, and J. Demengeot. 2002. IFN-αβ enhances BCR-dependent B cell responses. Int. Immunol. 14: 411-419.
63. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173: 2134-2142.
64. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202: 8-32.
65. Radhakrishnan, R., L. J. Walter, A. Hruza, P. Reichert, P. P. Trotta, T. L. Nagabhushan, and M. R. Walter. 1996. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 4: 1453-1463.
66. Cohen, B., D. Novick, S. Barak, and M. Rubinstein. 1995. Ligand-induced association of the type I interferon receptor components. Mol. Cell. Biol. 15: 4208-4214.
67. Chakravarty, L., M. D. Zabel, J. J. Weis, and J. H. Weis. 2002. Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. Int. Immunol. 14: 139-146.
68. Fujimoto, M., Y. Fujimoto, J. C. Poe, P. J. Jansen, C. A. Lowell, A. L. DeFranco, and T. F. Tedder. 2000. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
69. Carel, J.-C., B. L. Myones, B. Frazier, and V. M. Holers. 1990. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J. Biol. Chem. 265: 12293-12299.
70. James, J. A., K. M. Kaufman, A. D. Farris, E. Taylor-Albert, T. J. A. Lehman, and J. B. Harley. 1997. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 100: 3019-3026.
71. Kang, I., T. Quan, H. Nolasco, S. H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft. 2004. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172: 1287-1294.